A Phase 2 interventional study of Placebo and Cariprazine in Depression, Bipolar, sponsored by Forest Laboratories. Completed at 88 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-05-01.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Bipolar Disorder by AbbVie — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · AbbVie.
Among the 11 studies in Bipolar Disorder by AbbVie, this one has the largest enrollment, is the only one that started in 2011, is one of 6 in phase 2, and was the 5th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →2 of the 11 studies in Bipolar Disorder by AbbVie are open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 584 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 234 across the 11 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
2 of the studies in Bipolar Disorder by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07071532AbbVieA Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder | 2027-02 |
| NCT06696755AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Bipolar Disorder by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study was to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of participants with bipolar depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo orally once a day for 8 weeks.
Drug: Placebo
Participants received cariprazine 0.5 mg orally once on Days 1-2 and cariprazine 0.75 mg orally once a day starting on Day 3 for the remainder of the 8 week treatment period.
Drug: Cariprazine
Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, and cariprazine 1.5 mg orally once a day starting on Day 8 for the remainder of the 8 week treatment period.
Drug: Cariprazine
Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, cariprazine 1.5 mg orally on Days 8-14, and cariprazine 3.0 mg orally once a day starting on Day 15 for the remainder of the 8 week treatment period.
Drug: Cariprazine
Placebo was supplied in capsules.
Cariprazine was supplied in capsules.
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale Total Score at Week 6
The Montgomery-Åsberg Depression Rating Scale is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. The scores on the 10 items are summed for a total score that can range from 0 to 60. A higher score indicates greater depression. A negative change score indicates improvement.
Time frame: Baseline to Week 6
Change From Baseline in the Clinical Global Impressions-Severity Total Score at Week 6
The Clinical Global Impressions-Severity scale is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The participant is rated on a scale from 1 to 7 with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A higher score indicates greater illness. A negative change score indicates improvement.
Time frame: Baseline to Week 6
Adult participants with a diagnosis of bipolar I disorder with a current major depressive episode were considered for participation in the study.
| Milestone | Placebo | Cariprazine 0.75 mg | Cariprazine 1.5 mg | Cariprazine 3.0 mg |
|---|---|---|---|---|
| Started | 148 | 143 | 147 | 146 |
| Received treatment | 145 | 141 | 146 | 146 |
| Completed | 105 | 103 | 117 | 94 |
| Not completed | 43 | 40 | 30 | 52 |
| Withdrew: Did not receive treatment | 3 | 2 | 1 | 0 |
| Withdrew: Adverse event | 15 | 12 | 12 | 17 |
| Withdrew: Insufficient therapeutic response | 5 | 5 | 2 | 4 |
| Withdrew: Protocol violation | 5 | 2 | 3 | 7 |
| Withdrew: Withdrawal of consent | 11 | 9 | 4 | 15 |
| Withdrew: Lost to follow-up | 4 | 8 | 7 | 9 |
| Withdrew: Other miscellaneous reasons | 0 | 2 | 1 | 0 |
The Montgomery-Åsberg Depression Rating Scale is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. The scores on the 10 items are summed for a total score that can range from 0 to 60. A higher score indicates greater depression. A negative change score indicates improvement.
| units on a scale | Placebo | Cariprazine 0.75 mg | Cariprazine 1.5 mg | Cariprazine 3.0 mg |
|---|---|---|---|---|
| Change From Baseline in the Montgomery-Åsberg Depression Rating Scale Total Score at Week 6 | -11.1 ± 0.9 | -13.0 ± 0.9 | -15.1 ± 0.8 | -13.7 ± 0.9 |
The Clinical Global Impressions-Severity scale is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The participant is rated on a scale from 1 to 7 with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A higher score indicates greater illness. A negative change score indicates improvement.
| units on a scale | Placebo | Cariprazine 0.75 mg | Cariprazine 1.5 mg | Cariprazine 3.0 mg |
|---|---|---|---|---|
| Change From Baseline in the Clinical Global Impressions-Severity Total Score at Week 6 | -1.0 ± 0.1 | -1.1 ± 0.1 | -1.4 ± 0.1 | -1.3 ± 0.1 |
Collected over Adverse Events were collected and recorded from the time the participant signs the informed consent form until 30 days after the last dose of treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/145 (0%) | 5/145 (3.4%) | 42/145 (29%) |
| Cariprazine 0.75 mg | 0/141 (0%) | 1/141 (0.7%) | 43/141 (30.5%) |
| Cariprazine 1.5 mg | 0/146 (0%) | 2/146 (1.4%) | 51/146 (34.9%) |
| Cariprazine 3.0 mg | 0/146 (0%) | 2/146 (1.4%) | 56/146 (38.4%) |
| Event | Placebo | Cariprazine 0.75 mg | Cariprazine 1.5 mg | Cariprazine 3.0 mg |
|---|---|---|---|---|
| DepressionPsychiatric disorders | 1/145 | 1/141 | 0/146 | 0/146 |
| HemiparesisNervous system disorders | 1/145 | 0/141 | 0/146 | 0/146 |
| ManiaPsychiatric disorders | 1/145 | 0/141 | 0/146 | 0/146 |
| Suicidal ideationPsychiatric disorders | 1/145 | 0/141 | 0/146 | 0/146 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/145 | 0/141 | 0/146 | 0/146 |
| FallInjury, poisoning and procedural complications | 0/145 | 0/141 | 1/146 | 1/146 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/145 | 0/141 | 0/146 | 1/146 |
| InjuryInjury, poisoning and procedural complications | 0/145 | 0/141 | 1/146 | 0/146 |
| Vertigo CNS originNervous system disorders | 0/145 | 0/141 | 0/146 | 1/146 |
| HypomaniaPsychiatric disorders | 0/145 | 0/141 | 1/146 | 0/146 |
| Event | Placebo | Cariprazine 0.75 mg | Cariprazine 1.5 mg | Cariprazine 3.0 mg |
|---|---|---|---|---|
| AkathisiaNervous system disorders | 2/145 | 4/141 | 7/146 | 21/146 |
| HeadacheNervous system disorders | 17/145 | 11/141 | 11/146 | 10/146 |
| InsomniaPsychiatric disorders | 12/145 | 16/141 | 10/146 | 17/146 |
| NauseaGastrointestinal disorders | 7/145 | 12/141 | 12/146 | 12/146 |
| DiarrhoeaGastrointestinal disorders | 10/145 | 2/141 | 9/146 | 3/146 |
| SomnolenceNervous system disorders | 7/145 | 6/141 | 10/146 | 10/146 |
| RestlessnessPsychiatric disorders | 5/145 | 4/141 | 4/146 | 9/146 |
Safety population: All randomized participants who received at least 1 dose of investigational product.
| Age, Continuous(years) | Placebo | Cariprazine 0.75 mg | Cariprazine 1.5 mg | Cariprazine 3.0 mg | Total |
|---|---|---|---|---|---|
| Mean | 43.6 ± 12.0 | 40.1 ± 11.2 | 40.9 ± 11.4 | 42.8 ± 10.8 | 41.9 ± 11.4 |
| Sex: Female, Male(Participants) | Placebo | Cariprazine 0.75 mg | Cariprazine 1.5 mg | Cariprazine 3.0 mg | Total |
|---|---|---|---|---|---|
| Female | 89 | 91 | 92 | 88 | 360 |
| Male | 56 | 50 | 54 | 58 | 218 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Cariprazine 0.75 mg | Cariprazine 1.5 mg | Cariprazine 3.0 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 12 | 13 | 11 | 12 | 48 |
| Not Hispanic or Latino | 133 | 128 | 135 | 134 | 530 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Cariprazine 0.75 mg | Cariprazine 1.5 mg | Cariprazine 3.0 mg | Total |
|---|---|---|---|---|---|
| White | 110 | 111 | 109 | 113 | 443 |
| Black or African-American | 30 | 26 | 30 | 26 | 112 |
| Asian | 1 | 1 | 2 | 0 | 4 |
| American Indian or Alaska Native | 2 | 1 | 1 | 3 | 7 |
| Other | 2 | 2 | 4 | 4 | 12 |
| Weight(kg) | Placebo | Cariprazine 0.75 mg | Cariprazine 1.5 mg | Cariprazine 3.0 mg | Total |
|---|---|---|---|---|---|
| Mean | 79.98 ± 17.08 | 80.81 ± 18.36 | 81.43 ± 16.79 | 81.45 ± 17.86 | 80.92 ± 17.49 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Cariprazine 0.75 mg | Cariprazine 1.5 mg | Cariprazine 3.0 mg | Total |
|---|---|---|---|---|---|
| Mean | 27.81 ± 5.27 | 28.42 ± 5.71 | 28.44 ± 5.39 | 28.28 ± 5.64 | 28.24 ± 5.50 |
| Waist circumference(cm) | Placebo | Cariprazine 0.75 mg | Cariprazine 1.5 mg | Cariprazine 3.0 mg | Total |
|---|---|---|---|---|---|
| Mean | 91.40 ± 14.24 | 93.32 ± 15.45 | 93.38 ± 14.55 | 93.24 ± 15.40 | 92.83 ± 14.90 |
Ran from Jul 2011 to primary completion in Jan 2014, 29 months.
Results were first posted in May 2018, 4 years 3 months after primary completion. A results delay was requested in Feb 2015.
Of 56 phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 29 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine